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Abstract: Levels of total human kallikrein 2 (hK2), a protein involved the pathology of 
prostate cancer (PCa), could be used as a biomarker to aid in the diagnosis of this disease. 
In this study, we report on a porous silicon antibody immunoassay platform for the 
detection of serum levels of total hK2. The surface of porous silicon has a 3-dimensional 
macro- and nanoporous structure, which offers a large binding capacity for capturing probe 
molecules. The tailored pore size of the porous silicon also allows efficient immobilization 
of antibodies by surface adsorption, and does not require chemical immobilization. 
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Monoclonal hK2 capture antibody (6B7) was dispensed onto P-Si chip using a piezoelectric 
dispenser. In total 13 × 13 arrays (169 spots) were spotted on the chip with its single spot 
volume of 300 pL. For an optimization of capture antibody condition, we firstly performed 
an immunoassay of the P-Si microarray under a titration series of hK2 in pure buffer (PBS) 
at three different antibody densities (75, 100 and 145 µg/mL). The best performance of the 
microarray platform was seen at 100 µg/mL of the capture antibody concentration (LOD was 
100 fg/mL). The platform then was subsequently evaluated for a titration series of  
serum-spiked hK2 samples. The developed platform utilizes only 15 µL of serum per test 
and the total assay time is about 3 h, including immobilization of the capture antibody. The 
detection limit of the hK2 assay was 100 fg/mL in PBS buffer and 1 pg/mL in serum with a 
dynamic range of 106 (10−4 to 102 ng/mL).  
Keywords: porous silicon; human kallikrein 2; antibody microarrays; prostate cancer 
 
1. Introduction 
Human tissue kallikrens (hKs) are secreted from human proteases with diverse expression and 
physiological roles [1]. They consist of 15 (hK1-hK15) genes located on chromosome 19, in the 
q13.3–13.4 region. Among them, three kallekreins (hK1, hK2 and hK3) have high amino acid 
homology each other. hK2 and hK3 (PSA) share 80% amino acids while KLK1 shows 62% to 67% 
homology with PSA and hK2, respectively [2]. As a biomarker of prostate cancer, the levels of 
prostate specific antigen (PSA or hK3) in the serum, originating from leakage of pathological tissue to 
the vascular system, are routinely measured, and have been shown to be proportional to the tumor 
burden [3]. Even though it is the most commonly used biomarker for diagnosis of prostate cancer, and 
PSA screening tests are reported to have a significant correlation with 20% reduction in cancer 
mortality, a PSA concentration above the frequently used diagnosis cutoff (3–4 ng/mL) does not 
necessarily mean cancer as the serum PSA assay lacks specificity, i.e., the capability of distinguishing 
prostate cancer from some non-malignant prostatic pathologies such as benign prostatic hyperplasia or 
prostatitis [4], with the drawback of requiring unnecessary painful biopsies because of the low 
specificity [5]. It should also be noted that only 25% of men with slightly elevated PSA levels do have 
PCa [5]. In addition, a PSA concentration below the cutoff may actually be cancer. Moreover there are 
strong arguments challenging the usefulness of PSA screening tests because of the large discrepancies 
between decreasing disease aggressiveness and increasing levels of treatment. This has led to 
widespread criticism that prostate cancer is now an “overdiagnosed” and “overtreated” cancer [6]. 
Therefore, requirement for additional prostatic tumor markers are increasingly high. 
Some other kallikrein family proteins are recognized as useful biomarkers of prostate cancer. It is 
reported that higher KLK4 mRNA levels in the prostate tissue obtained by biopsy are correlated with 
prognosis and cancer stage [7]. Kallikrein-related peptidase 5 (KLK5) is overexpressed in normal tissues 
compared to cancerous prostatic ones and it shows an inverse relationship between KLK5 levels and 
pathologic tumor stage [8]. Moreover, elevated KLK 11 mRNA expressions have been found to be 
associated with a less advanced stage, and an optimistic disease course for prostate cancer [7]. Human 
Sensors 2015, 15 11974 
 
 
kallikrein 2 (hK2) is a serine protease with trypsin-like specificity and has many similarities to PSA. 
Since the expression of hK2 protein is higher in malignant prostatic tissue versus benign tissue it has 
been also considered as a prostate cancer (PCa) biomarker since levels of hK2 in serum from PCa 
patients are increased relative to individuals with BPH [9–12]. Expression analysis by RT-PCR has 
shown the down-regulation of PSA mRNA, while hK2 mRNA is up-regulated in aggressive  
tumors [13]. It is suggested that hK2 could also be useful in predicting pathologic stage and grade 
along with biochemical outcome in patients treated with radical prostatectomy [14]. In patients with 
mildly elevated PSA levels, hK2 acts as an independent predictor for PCa diagnosis [15]. Moreover, 
hK2 might be suggested as a potential biomarker in diagnosing poorly differentiated tumors [16], as 
well as differentiating between organ-confined cancer and extra-capsular disease [17]. 
The concentration of hK2 in human prostates is approximately 10%–50% of the PSA level and it is 
50- to 100-fold lower than the PSA concentration in blood serum [18,19]. Despite the intrinsically low 
expression levels of hK2, development of sensitive assay methods of hK2 is insufficient compared to 
that of PSA assay [20–24]. Only the Dissociation-Enhanced Lanthanide Fluorescent Immunoassay, the 
so called DELFIA system that utilizes the unique chemical properties of lanthanide chelates in concert 
with time-resolved fluorescence (TRF) detection, has reported a limit of detection of hK2 in the  
low pg/mL with a 103 order (3 pg/mL to 3 ng/mL) dynamic range [10,25]. This method requires 
laborious labeling procedures and a sophisticated optical system. Therefore, a robust, simple but highly 
sensitive assay technology for hK2 detection is still required. 
The 3-D macro-pore structures of the P-Si enlarges the surface area for immobilization [26,27] and 
hence results in an increased density of capture antibody on the surface [28]. Since physical adsorption 
is the main method to bind the antibody on the surface, it provides fast immobilization of capture 
antibody (after less than a few minutes of incubation) without any chemical treatment on the  
surface [28]. Antibody or protein (such as IgG and Protein A) is strongly adsorbed on the silicon 
surface when the molecules are dispensed as small droplets and the droplets are quickly dried  
out [26–28]. Numerous factors, including pore size, protein size, surface chemistry and layer thickness, 
will influence the amount of protein adsorbed, as well as its structure and function [29,30]. There are 
hundreds of different cross-linking reagents available, resulting in covalent binding between the 
biomolecules and silicon surface, however, it is very beneficial to find a surface that adsorbs protein 
spontaneously since derivation might affect the other surface properties, such as hydrophobicity, 
fluorescent background and surface charges [30]. 
P-Si enables one to set up a sensitive and simple assay protocol compared to the other proposed 
amplification methods such as modifying the detection antibodies, by e.g., dendritic amplification [31], 
catalyzed signal amplification with colorimetric readout [32,33] or detection with rolling-circle 
amplification [34]. We previously developed a P-Si (porous silicon) antibody microarray  
platform for analyzing prostate specific antigen (PSA) in serum [24] and α-synuclein in cerebrospinal 
fluid (CSF) [35] with high sensitivity and reproducibility. P-Si with sub-micron pores is optimal for 
antibody immobilization. We investigated immunoassays using a P-Si microarray at three different 
capture antibody (PSA––prostate specific antigen) concentrations, analyzing the influence of the 
antibody density on the assay detection sensitivity. The microarray showed a LOD of 800 fg/mL and a 
dynamic range of 800 fg/mL to 80 ng/mL in serum-spiked PSA [24]. Usage of our P-Si microarray 
also extends to α-synuclein in CSF which is one of the potential biomarker of Parkinson’s disease. The 
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porous silicon microarray displayed a 35 pg/mL LOD and a dynamic range of four orders of 
magnitude (17 pg/mL to 500 ng/mL) [35]. The substrate is well suited for surface-based immunoassays 
because the micro- and nonporous structure of the substrate adsorbs antibodies in an intact state on the 
enlarged 3-D surface. It can be noted that this surface is also compatible with mass spectrometric 
readout [28,36]. Table 1 present several supports materials for microarrays and their respective 
advantages and disadvantages. 
Table 1. Solid microarray supports. 
 Derivatized Glass Filter/Membrane Gel Pad/Agarose Film Porous Silicon 
Advantages Cheap Low cost High sample capacity High sample capacity 
 
Compatible with 
most micro-arrayers 
Reusable  Spot homogeneity 
    Low unspecific binding 
Disadvantages 
Non-uniform spots 
(Coffee ring effect) 
Limit of spot density Expensive Laborious procedures 
   Laborious procedures  
The protein/antibody microarray format should ultimately be used not only for qualitative analysis 
such as profiling the abundance of thousands of proteins [37,38], or globally analyzing protein 
phosphorylation [39], but also to evolve into the development of a quantitative approach [40,41]. 
Although the potential of protein microarray technology was foreseen more than 20 years ago by  
Ekins [42], it is only recently that it started to find its way into proteomics research, diagnosis and drug 
discovery [43–45]. 
Sandwich immunoassays are widely used for diagnostics, frequently in 96 well formats. They 
consist of a pair of antibodies (capture antibody and detection antibody) that bind to the target 
biomarkers in a sandwich format. Sandwich assays offer high detection sensitivity resulting from the 
enrichment of the target proteins by the capture antibody [46,47]. 
In this study, we developed a P-Si-based antibody microarray platform for improving the detection 
sensitivity of the hK2 assay. Detection sensitivity and dynamic ranges of the P-Si assay platform were 
investigated by varying the density of the capture antibody on the spots. Figure 1 shows the procedures 
of the developed hK2 immunoassay. Three different concentrations of capturing antibody were arrayed 
on a porous silicon chip and evaluated in the detection hK2 in buffer (PBS). The P-Si antibody 
microarray format, with optimized capture antibody concentration, was subsequently evaluated in the 
detection of hK2 spiked into human female serum. We also investigate the cross-reaction between hK2 
capture antibodies and PSA antigen since PSA and hK2 antigen have high homology [9,10]. HK2 
capture antibodies were dispensed on the P-Si chip and PSA spiked serum samples were incubated on 
the chip for testing the level of cross-reaction. The developed platform has the advantages of low sample 
consumption, time efficiency and robustness. It took in total time of around 3 h from dispensing the 
capture antibody on the surface to the end of the immunoassay. 
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Figure 1. Schematic of the P-Si chip immunoassay procedure, starting with the dispensing 
of hK2 capture antibodies onto the porous silicon surface. The porous silicon chip  
with physically adsorbed antibodies is placed into an assay well made of  
polydimethyl-polysiloxane (PDMS), and hK2-containing serum samples are added; the 
size of the PDMS assay is well suited for each P-Si chip and makes it easy to perform 
parallel pipetting. Subsequently, detection antibody (polyclonal primary and Alexa 488 
labeled secondary antibody) is used for measuring fluorescent signals under a microscope. 
2. Experimental Section 
2.1. P-Si Fabrication  
The porous silicon fabrication is governed by various etching parameters such as HF  
concentration, current density, anodization time, illumination, orientation of crystal, silicon types, 
doping level, etc. [39]. The porous silicon fabrication procedure in this paper followed optimum 
antibody immobilization conditions described previously [48]. Briefly, silicon, 6–8 Ω·cm resistivity 
(boron doped p-type), <100> orientation, was purchased from Addision Engineering (San Jose, CA, 
USA). The wafer was placed in an electrochemical-etching cell. The electrolyte solution consisted of 
3.6% hydrofluoric acid and 90.7% dimethylformamide (Merck, Darmstad, Germany). The silicon was 
anodized for 70 min with backside illumination. Current density during anodization was 90 mA/m2, 
after which the silicon was washed in ethanol three times and diced into 3 mm × 3 mm pieces to fit a 
microtiter plate format (Corning Costar Corporation, Cambridge, MA, USA). 
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2.2. PDMS Well 
A 45 mm× 70 mm size and 5 mm thickness polydimethylpolysiloxane (PDMS) slab was prepared 
to well format as seen in Figure 2. The slab was fabricated with a Syglad 184 kit (Dow Corning Toray, 
Tokyo, Japan) that contains a PDMS monomer base and a curing elastomer reagent. The base and 
curing reagent were mixed in 10:1 weight ratio, and poured over a flat surface (i.e., silicon or glass). The 
mixture was kept at 0.02 MPa for 30 min in a vacuum chamber to remove the trapped air bubbles from 
the liquid PDMS. After removing the bubbles, the mixture were baked at 70 °C for 1 h. Finally, 9 mm 
holes were punched on the PDMS slab to set up PDMS wells. 
 
Figure 2. Porous silicon (P-Si) matrix used for microarrays. P-Si chips and PDMS wells  
(a) Capture antibody spotted P-Si chips were located in the wells to start the immunoassay.  
The scanning electron micrographs show a sequential zoom into a typical surface;  
(b) Macro-pores of micrometer size are clearly seen, combined with a micro- and  
nano-morphology (pore size around sub-µm to µm). 
2.3. Proteins and Reagents 
The monoclonal mouse antibody against hK2 (6B7, ab40749) was obtained by Abcam (Cambridge, 
UK). The polyclonal goat anti–hK2 antibody (PAB7226) and Alexa Fluor 488 labeled donkey  
anti-goat (ab150129) antibody were obtained at Abnova (Taipei City, Taiwan) and Abcam, 
respectively. Recombinant hK2 (ATGP2175) was obtained from ATGen (Pankyo, Korea) and prostate 
specific antigen (PSA) from human semen was obtained from Sigma-Aldrich (St. Louis, MO, USA). 
2.4. Analytical Samples 
Female single donor serum was purchased from BBI Solutions (S122–1, Cardiff, UK) and stored at 
−80 °C following the company’s recommendations. The serum was spiked with the recombinant hK2 
in a titration series ranging from 100 fg/mL to 100 ng/mL. 
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2.5. Sandwich Assay 
Monoclonal mouse capture antibody (6B7) for hK2 was dispensed onto the porous silicon chip,  
3 × 3 mm size, using a piezoelectric dispenser (DW Scienion AB, Berlin, German) with a spot to spot 
distance of 150 µm. The antibodies were immobilized on the chip surface by physical adsorption.  
A drop volume was around 300 pL and a 13 × 13 (169 spot) array was spotted on the surface for each 
array. The microarray chips were placed in the PDMS well plates for the immunoassay. The porous 
silicon microarray immunoassay was evaluated using samples with hK2 spiked into both pure buffer 
(PBS) and female serum to obtain a final concentration ranging from 100 fg/mL to a few 100 ng/mL. 
The following steps were performed at room temperature: 
1 After arraying the antibody, the chips were washed three times using 10 mM PBS to remove 
loosely bound antibodies. 
2 The chips were incubated for 1 h in 100 µL blocking solution (5% (w/v) non-fat dry milk in  
PBS (Bio-Rad, Hercules, CA, USA)) to prevent non-specific binding and washed  
3 times using 0.05% Tween 20 in 10 mM PBS. 
3 Following blocking, the chips were incubated with 15 µL of spiked sample for 1 h, then washed (as 
above) and subsequently incubated with 15 µL of detection antibody (polyclonal goat anti-hK2). 
4 After another washing step, 15 µL of AF488 labeled anti-goat polyclonal antibody was added 
onto the chips and incubated for 1 h. 
5 Finally, the chips were washed three times and dried at room temperature. 
6 The fluorescent spots images were observed using a eclipse TE2000-U fluorescence 
microscope (Nikon, Tokyo, Japan). 
7 The captured images were analyzed by the open source image-processing tool Image J. 
2.6. Mean Spots Intensities and Limits of Detection 
The mean intensities of spots were measured and quantified by Image J among all microarray spot 
images, we selected nine spots (a 3 × 3 array) on each P-Si chip for quantification of the data since 
they fitted well in a single screen image. A total of 18 spots were chosen for data analysis since all 
experiments were performed on two independent chips. The spot intensities (S) were measured and 
quantified across the area. The local background (B) was collected in the same way and subtracted 
from the spot signals, generating mean spots intensities (S-B) as presented in the graphs. Mean spot 
intensity (S-B) can be defined as ∑ (ܵ − ܤ)௡/݊௡ଵ . The limit of detection (LOD) was followed 3-sigma 
(ߪ) defined as the lowest detectable signal from 3-sigma standard deviation above the mean spot 
intensities of negative control (N). The choice of LOD can be written as > (ܵ − ܤ)ே + 3ߪ, when 
(ܵ − ܤ)ே is mean spot intensity of negative control (N) and ߪ is standard deviation of negative control. 
3. Results and Discussion 
3.1. General Remarks 
Surface bound immunoassays generally become more sensitive when the affinity or/and the density 
of the capture antibody increases [48]. The 3-D morphology of the micro/nano porous silicon surface 
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layer offers a high antibody immobilization capacity and hence an increased antibody density per spot 
area [24,28]. Figure 2 shows macroporous layers with a characteristic size of sub micro −1 µm on the 
silicon surface recorded by Field Emission Scanning Electron Microscopy (FESEM). 
3.2. hK2 Assay Performance against Density of Capture Antibody 
To optimize the P-Si hK2 immunoassay, we first evaluated the assay sensitivity by arraying the 
capture antibody, 6B7, at three different concentrations and performing the hK2 immunoassay in PBS 
buffer (10 mM, pH 7.2). Figure 3 shows a titration series of hK2 against three different capture 
antibody concentrations (75, 100 and 145 µg/mL).  
 
Figure 3. Titration series of hK2 in buffer (PBS) solution at three different concentrations 
of the capturing antibody 6B7 (75 µg/mL, 100 µg/mL and 145 µg/mL). The LOD was 
found to be 1 pg/mL when the capturing antibody was 75 µg/mL and was reduced to  
100 fg/mL when the capturing antibody concentrations were 100 µg/mL. The LOD became 
1 pg/mL again when concentration of the antibody was 145 µg/mL. 
Increasing concentrations of capture antibody yielded elevated fluorescent signals. However, the 
negative control (N) signal also increased at higher density of the antibody. The coefficient of variance 
(C.V) and mean spot intensities of arrays were shown in a right side of the figure. The fluorescent 
signal level of negative control (N) increased up to 70% (mean spot intensity is around 3) at a capture 
antibody concentration of 145 µg/mL compared to those at 75 and 100 µg/mL (mean spot intensity is 
around 2 at capture antibody 75 µg/mL and 1.95 at 100 µg/mL). In most cases, spot reproducibility 
within the chips shows good reliability (CVs~10%–20%) and also was in agreement with earlier 
results [33]. The linear regression of the mean spot intensities versus hK2 concentration corresponded 
to a coefficient of determination (R2) equal to 0.97, 0.99 and 0.906 for capture antibody concentrations 
of 75, 100 and 145 µg/mL, respectively. 
It was hypothesized that the unspecific binding between the capture antibody and the secondary or 
the detection antibody increased at elevated capture antibody concentrations. To define the limit of 
detection, we chose 3-sigma (σ) method, which is the lowest signal detection at least three times above 
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the standard deviation of the negative control (N). At a capture antibody concentration of 75 µg/mL the 
limit of detection (LOD) was found to be 1 pg/mL and at a capture antibody concentration of  
100 µg/mL the LOD was improved by one order of magnitude to 100 fg/mL. We believe that the  
100 fg/mL LOD reported for hK2 is competitive with the results of the DELFIA system for which a 
sub pg/mL LOD is reported [10,25]. 
A further increased density of capture antibody (145 µg/mL) did not yield an improved LOD as this 
also resulted in a significantly increased negative control level. The dynamic range was 105 (10−3 to  
102 ng/mL) at a capture antibody concentration of 75 µg/mL and increased to 106 (10−4 to 102 ng/mL) 
when the capture antibody concentration was 100 µg/mL. The signal intensities were enhanced in 
proportion to the concentration of the capturing antibody, which followed the expectations of 
improved LOD with increased surface density of the capture antibody. However in case of 145 µg/mL 
capture antibody, the readout signal intensity drastically increased up to 100 pg/mL of hK2 level and it 
was saturated at higher concentrations (over 1 ng/mL hK2 level). The dynamic range therefore, 
defined a 102 order (from 1 pg/mL to 100 pg/mL), which was reduced by two orders of magnitude. 
3.3. hK2 Immunoassay in Female Human Serum 
We evaluated the P-Si immunoassay platform subsequently in human serum since the final purpose 
of our platform development is to quantify the levels of hK2 in clinical samples. Initially, a high 
concentration of recombinant hK2 (over a few µg/mL) was spiked into a serum sample and the spiked 
samples were serially diluted up to 106 times with serum to achieve total hK2 levels ranging from a 
hundred fg/mL to a hundred ng/mL. As a negative control we assayed unspiked serum. 
 
Figure 4. hK2-spiked human female serum analyzed with the sandwich microarray at two 
different capturing antibody concentrations (75 µg/mL and 100 µg/mL). The LOD was  
10 pg/mL and 1 pg/mL when the concentrations of capture antibody were 75 µg/mL and  
100 µg/mL, respectively. Increased assay sensitivity was observed with an elevated 
concentration of the capturing antibody (6B7). The negative signal also increased at the 
higher concentrations of the capture antibody. 
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We chose to spot capture antibody concentrations of 75 µg/mL and 100 µg/mL since they showed 
good assay readouts with a minimum negative (N) control (Figure 3). The corresponding titration 
series of hK2 in female serum was recorded for microarrays with the two different antibody 
concentrations (Figure 4). In the case of the 100 µg/mL antibody concentration, spot intensities could 
not be clearly distinguished against the negative controls (N) at an hK2 level of 100 fg/mL. The spot 
intensity of 1 pg/mL was however clearly distinguished (over 3 σ) from the negative control (N), and 
was defined as the LOD in the serum sample experiments. In the case of a capture antibody 
concentration of 75 µg/mL the signals were not distinguishable against the negative control until a 
level of 10 pg/mL of hK2 was reached (Figure 4).  
From the sensitivity point of view, the serum spiked hK2 immunoassay at 75 µg/mL of capture 
antibody concentration showed the best assay performance. Total assay time is less than 3 h, which 
included 40 min for each blocking, sample incubation, primary antibody incubation and secondary 
incubation. All the microarray experiments had a coefficient of variation (CV) of less than 25%, 
indicating good spot reproducibility of the chips. The negative control signal (N) increased up to 100% 
as compared to the PBS buffer readout. This may be explained by cross-reaction of the antibody in the 
complex serum sample. Since serum contains various components such as nucleotides, peptides and 
proteins, one or some of these contents might have a cross-reaction with the antibodies. The intensity 
of the negative signal (N) is similar to the pg/mL level of hK2 in pure buffer condition and all 
intensities of serum sample are higher than those in PBS, which indicates a correlation between 
antibodies and serum. 
Since the negative signal intensity (N) of the serum was similar to the intensity of 1 pg/mL of hK2 
spiked PBS buffer sample, we further evaluated the platform through a serum PBS dilution series at 
four different concentrations (1/50, 1/10, 1/5, and 1/2). The microarray chips with 100 µg/mL of 
capture antibody were used for immunoassay of the four-dilution serum sample. Figure 5 shows 
readout signals of the microarray against the diluted serum samples. Dwindling signal was observed 
down to 50 times dilution. It could be caused by cross-reaction of several components in the serum to 
capture antibody and/or it also might be considered that intrinsic hK2 exists even in female serum that 
is extremely low levels not detected by a normal ELISA format. 
 
Figure 5. Immunoassay signals of the diluted serum samples. Serum samples were diluted 
down to 50 times and the samples were immunoassayed on microarray chips. The 
concentration of capture antibody was 100 µg/mL. Mean spot intensities and coefficients 
of variant are presented with spot images in the left panel. 
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3.4. Cross Reaction of hK2 Antibody against PSA 
Since human kallikrein 2 (hK2) has a high homology to prostate specific antigen (PSA) there is a 
critical need to carefully determine the hK2 assay design against PSA. We therefore performed  
serum- spiked PSA assays using the hK2 antibody microarrays to investigate the ratio of cross-reaction 
between PSA and hK2. We dispensed hK2 capture antibody with 100 µg/mL concentration on P-Si 
substrates and performed immunoassays of PSA-spiked serum at four different concentration (5, 50 
and 500 ng/mL and 5 µg/mL). Figure 6 shows the readout microarray signals of PSA-spiked serum 
with negative control. All four signals of PSA-spiked serum are not significantly different from that of 
the negative control, from which it can be determined that there is no cross-reaction between hK2 
capture antibody and PSA. The developed P-Si microarray platform therefore, is sufficient to quantify 
of hK2 abundance in serum without worrying about any cross-reaction with PSA. 
 
Figure 6. Cross-reaction tests of hK2 antibody spots against PSA spiked serum. 
Immunoassay signal of negative control (female serum sample) was compared with four 
PSA-spiked serum samples (5, 50 and 500 ng/mL and 5 µg/mL). HK2 capture antibody 
was spotted on P-Si chips at a concentration of 100 µg/mL. 
4. Conclusions 
This paper reports a simple and robust detection methodology for hK2 determination in serum 
samples. The large surface area of the tailored porous silicon used enables a fast and simple antibody 
immobilization by physisorption, and allows improved detection sensitivity and a broad dynamic 
range. The amount of antibody consumed on one chip was around 33.8 fmol (one spot is around  
200 amol and the array has a 13 × 13 format), which is an exceptionally small amount compared to 
conventional ELISA formats. 
The porous silicon microarray displayed a 100 fg/mL LOD and a dynamic range of 106 (10−4 to  
102 ng/mL) under optimized capture antibody conditions. The developed assay platform also worked 
well in human serum and showed a LOD of 1 pg/mL and a dynamic range of 104 (1 pg/mL to  
10 ng/mL). 
The simple physical-adsorption antibody immobilization avoided laborious and time-consuming 
chemical immobilization procedures, which shortens the overall assay time. It makes it possible to start 
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the immunoassay a few minutes after the antibody immobilization process. The total assay time was 
about 3 h, including the antibody immobilization. Recent studies report that either the level of hK2 
alone or in combination with total PSA (tPSA) or free PSA (fPSA) might improve prediction of PCa 
stage and risk of biochemical cancer recurrence after radical prostatectomy (RP) [49,50]. Since our assay 
can detect one or two orders of magnitude lower amounts of hK2 compared to the highly optimized 
ELISA system [10,25] it could contribute to future clinical practice by enabling more accurate 
diagnosis of prostate cancer patients. The usage of our microarray format can be extended to real clinical 
experiments for minimizing overdiagnosis of PCa, by evaluating hK2 levels in screened cohorts of men 
with PCa and higher PSA level, enrolled in first PSA screening rounds [49]. The simple method also 
has the merit of shortening the otal assay time and this makes it possible to analyze a large number of 
samples in time-saving way. Lastly, the large sample sizes have a significant positive influence on the 
power of statistical analysis. 
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